ANZ 9311. Phase III trial to compare the effect of a short high dose intensive course of chemotherapy with filgrastim support versus a conventional standard dose course of chemotherapy in patients with advanced breast cancer.
Australia and New Zealand Breast Cancer Trials Group Ltd
225 participants
Feb 2, 1994
Interventional
Conditions
Summary
Phase III trial to campare the effect of a short high-dose intensive course of chemotherapy with filgrastim support versus a conventional standard-dose course of chemotherapy in patients with advanced breast cancer.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The purpose of the study is to compare a high dose epirubicin/cyclophosphamide (EC) chemotherapy regimen, plus Filgrastim support, given over a 9 week period with a standard epirubicin/cyclophosphamide (EC) chemotherapy regimen given over 18 weeks. The total dose of EC is the same.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000478617